Neuroprotective agents for clinical trials in ALS: a systematic assessment.
about
Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosisInsulin-like growth factor-I for the treatment of amyotrophic lateral sclerosisA comprehensive review of amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis: New Perpectives and UpdateCurrent approaches to enhance glutamate transporter function and expressionAmyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic TrialsHeat shock transcription factor 1 as a therapeutic target in neurodegenerative diseasesUsing gene expression signatures to identify novel treatment strategies in gulf war illnessMetformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female miceNordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosisTamoxifen and estradiol improved locomotor function and increased spared tissue in rats after spinal cord injury: their antioxidant effect and role of estrogen receptor alpha.Redox modifier genes and pathways in amyotrophic lateral sclerosis.Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis.Xenoestrogens regulate the activity of arginine methyltransferases.Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington's disease.A cell-based fascin bioassay identifies compounds with potential anti-metastasis or cognition-enhancing functions.Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research.The flaws and human harms of animal experimentation.Phenylbutyrate therapy for maple syrup urine disease.Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.Inhibiting drug efflux transporters improves efficacy of ALS therapeuticsSystemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosisTamoxifen and Src kinase inhibitors as neuroprotective/neuroregenerative drugs after spinal cord injuryMolecular chaperones in Parkinson's disease--present and futureRegulation of nuclear TDP-43 by NR2A-containing NMDA receptors and PTEN.Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS.Potential drugs and methods for preventing or delaying the progression of Huntington's disease.Heat shock protein 70: roles in multiple sclerosis.The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials.Strategic approaches to developing drug treatments for ALS.Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infectionDifferential roles of GluN2A- and GluN2B-containing NMDA receptors in neuronal survival and death.Catalytic antioxidants to treat amyotropic lateral sclerosis.Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis.Current clinical trials in amyotrophic lateral sclerosis.Cognition and amyotrophic lateral sclerosis (ALS).Huntington's disease: progress and potential in the field.Plant-derived triterpenoids and analogues as antitumor and anti-HIV agentsAmyotrophic lateral sclerosis (ALS): three letters that change the people's life. For ever.
P2860
Q21266563-0182FF7F-AAA9-47E5-9D54-D500E9152172Q24630353-88A7F86A-37CF-4700-B1AE-AEDFC8744D01Q26775401-F59145C0-1CB4-492B-A456-334549D93E77Q26781051-A0823336-8618-4DB5-BA85-8B3C559AE25BQ26996723-BADC1B1D-4F4E-4C9F-9B5A-5C7B62CAC4BAQ27021917-BF0470EB-DE5E-4490-BEAA-2480B29C73A8Q27026884-63D759FF-0F0C-4E4B-8722-AA978DC542E4Q28397964-5A6BBB89-D79C-4591-B13B-F54B02189942Q28476761-D47E53D7-AE82-4251-BD5A-0B491A701FEAQ33351549-4D14EF2E-435F-40ED-A73E-5835F1F7BC6BQ33715453-86B9D2A7-C4CA-4C12-A958-3C35AE57E3E0Q33742737-DD8D8B65-264E-4451-A31D-266DDA181153Q33745558-DD4BDA56-2906-4E56-A162-0E29153C93BEQ33796036-35490D56-6B64-4751-B99E-933FC57A0EDCQ34026859-CD87F182-1F5E-49E4-A97A-FA282A2E26D2Q34053585-2D6D17FC-4E28-4EC3-849B-4221673C9887Q34392217-93156A79-8D29-41C2-AC50-CF52D2F8BDF6Q34401653-DE66B7D6-1435-4F6E-B5DD-38E483514026Q34493876-E8AF23E1-3D12-4ED6-9DA9-570954DAF923Q34505609-851A8944-0E60-452E-8EA1-E4E07458A0F2Q34678136-7AC719F9-F626-4BC7-B20B-6A8234FDDB87Q34824777-F7313713-74F4-4AF1-8A4E-7F70180A8803Q35156359-7D6DF4B9-E83E-442B-8D84-40B61A99E59FQ35403338-40913AE7-0CC6-438A-82D0-13356AA07D2FQ35688796-A0213618-84E5-48E2-8DFF-0654A7128F47Q35912453-AA8E3947-0B0C-4AFC-83A3-3300B3D36E5BQ36007494-35839E57-028D-47AD-AD72-4F1D8A476426Q36142706-7DC9DFB1-B124-4CBB-9062-0B7CB0A61840Q36283450-46966EB7-CF86-4C59-904B-72EBBEA391A5Q36441993-30784343-013D-4517-B9E0-D27E3171F6AAQ36485321-92F7BDA3-7FF9-41F8-A884-AA2F6B9287ACQ36491096-D108596E-414E-49AE-92A9-4E8DE5E7857DQ36529884-9E82B65E-63CF-4BD3-B2C7-97DEE048D377Q36623068-42FB3C24-C1C9-449E-8169-48A6026750B2Q36866600-0710F1A4-FEFF-45F0-A268-32D4F9411E45Q36904850-7D5FA1A2-E80C-428C-8B10-7D3C199B855FQ36915818-AED30DA6-413D-4C28-9E85-2731AE2B6782Q37016096-EDF22DF7-683D-412F-A0C1-8403E37494D6Q37173329-2A846563-3992-4A1F-9274-2772E1F2CB01Q37590212-2A67221B-49F9-40C7-8457-42E51C8D4868
P2860
Neuroprotective agents for clinical trials in ALS: a systematic assessment.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Neuroprotective agents for clinical trials in ALS: a systematic assessment.
@ast
Neuroprotective agents for clinical trials in ALS: a systematic assessment.
@en
Neuroprotective agents for clinical trials in ALS: a systematic assessment.
@nl
type
label
Neuroprotective agents for clinical trials in ALS: a systematic assessment.
@ast
Neuroprotective agents for clinical trials in ALS: a systematic assessment.
@en
Neuroprotective agents for clinical trials in ALS: a systematic assessment.
@nl
prefLabel
Neuroprotective agents for clinical trials in ALS: a systematic assessment.
@ast
Neuroprotective agents for clinical trials in ALS: a systematic assessment.
@en
Neuroprotective agents for clinical trials in ALS: a systematic assessment.
@nl
P2093
P1433
P1476
Neuroprotective agents for clinical trials in ALS: a systematic assessment.
@en
P2093
Cudkowicz ME
Traynor BJ
P356
10.1212/01.WNL.0000223353.34006.54
P407
P577
2006-07-01T00:00:00Z